Understanding the contribution of individual amino acid residues in the binding of psychoactive substances to monoamine transporters by Senior, Tamara et al.
  
1 
Understanding the contribution of individual amino 
acid residues in the binding of psychoactive 
substances to monoamine transporters 
Tamara Senior, a Michelle J. Botha, a Alan R. Kennedy, b and Jesus Calvo-Castro*a 
 
a School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK. 
b Department of Pure & Applied Chemistry, University of Strathclyde, Glasgow, G1 1XL, UK. 
 
*Corresponding author: j.calvo-castro@herts.ac.uk  
 
ABSTRACT: The development of point-of-care detection methodologies for biologically 
relevant analytes that can facilitate rapid and appropriate treatment is at the forefront of current 
research efforts and interests. Among the various approaches, those exploiting host-guest 
chemistries where the optoelectronic signals of the chemical sensor can be modulated upon 
interaction with the target analyte are of particular interest. In aiding on their rational 
development, judicious selection of peripheral functional groups anchored to core motifs with 
desired properties is critical. Herein, we report an in-depth investigation of the binding of three 
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psychoactive substances, MDAI, mexedrone and phenibut to receptors of the monoamine 
transporters for dopamine, norepinephrine and serotonin, particularly focusing on the role of 
individual amino acid residues. We first evaluated the conformational flexibility of the ligands 
by comparing their experimentally determined crystal structure geometries to those optimised by 
means of quantum as well as molecular mechanics, observing significant changes in the case of 
phenibut. Molecular docking studies were employed to identify preferential binding sites by 
means of calculated docking scores. In all cases, irrespective of the monoamine transporter, 
psychoactive substances exhibited preferred interaction with the S1 or central site of the proteins, 
in line with previous studies. However, we observed that experimental trends for their relative 
potency on the three transporters were only reproduced in the case of mexedrone. Subsequently, 
to further understand these findings and to pave the way for the rational development of superior 
chemical sensors for these substances, we computed the individual contributions of each nearest 
neighbour amino acid residue to the binding to the target analytes. Interestingly, these results are 
now in agreement with those experimental potency trends. In addition, these observations were 
in all cases associated to key intermolecular interactions with neighbouring residues, such as 
tyrosine and aspartic acid in the binding of the ligands to the monoamine transporter for 
dopamine. As a result, we believe this work will be of interest to those engaged in the rational 
development of chemical sensors for small molecule analytes as well as to those interested in the 
use of computational approaches to further understand protein-ligand interactions.  
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INTRODUCTION 
Among the plethora of chemicals that regulate normal brain function, monoamine transporters 
(MATs) are widely considered to play a critically important role.1,2 Located in the plasma 
membranes of the monoaminergic neurons, they consist of 12 transmembrane helices and are 
responsible for the release or reuptake of the monoamines dopamine, norepinephrine and 
serotonin, which have biological roles spanning from mood stabilisation and appetite to sexual 
arousal and decision making.3–7 
 
Figure 1. Chemical structures for dopamine, norepinephrine and serotonin. 
Dopamine concentrations in the brain, which are modulated by the dopamine transporter (DAT), 
can be further modified by ligands that interact with the protein by either inhibiting the reuptake 
of dopamine and leading to feelings of euphoria or by stimulating the release of synaptic 
dopamine (i.e. amphetamine), associated to increased confidence and levels of energy.4,8,9 In 
turn, the serotonin monoamine transporter (SERT) is responsible for maintaining normal 
concentrations of serotonin in the brain, with unregulated concentrations resulting in a number of 
disorders such as anxiety, depression and impaired cognitive function.10,11 In relation to the 
norepinephrine transporter (NET), which recycles the three monoamines from the synapse to the 
presynaptic neurons, there exist a lesser number of selective ligands that have been identified to 
date in comparison to ligands which are selective towards the other two monoamine transporters, 
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which can be accounted for on the basis of the structural similarity between the DAT and the 
NET.12–15 The latter can be further ascribed to the large structural similarities among the three 
monoamines, particularly in the cases of dopamine and norepinephrine (Figure 1), leading to a 
degree of promiscuity between them and their associated transporters and furthermore to the 
development of drugs that exhibit affinities to all three monoamine transporters.3,7,12,16,17 Along 
those lines and associated to the extensive roles in cognitive and emotional processes played by 
monoamine transporters, drug substances such as cocaine, amphetamine and ecstasy, which are 
structurally related to the monoamines, have been extensively utilised recreationally to alter the 
monoamine transporter levels within the brain to elicit some form of psychoactive response.18–20 
More recently, the so-called Novel Psychoactive Substances (NPS), which denote compounds 
that intend to imitate the psychoactive effects of other controlled ones in an attempt to bypass 
existing regulations, have emerged in the illegal markets for recreational substances.21,22 
Primarily due to their associated fast rate of appearance and their low residence time in these 
markets, there is an acknowledged lack of easily accessible detection and identification platforms 
for NPS which prevents rapid and appropriate treatment. The latter further makes them                                          
a critical social and health problem of worldwide concern.23 Considering these characteristics of 
NPS, the development of point-of-care detection methodologies for NPS are at the forefront of 
research interests and efforts.24 
Drugs, recreational or therapeutical, act on target receptors via appropriate supramolecular 
interactions to either trigger or block its biological response. That concept, widely exploited by 
pharmacophore modelling approaches in ligand-based drug development methodologies,25–27 has 
also been utilised in the rational development of chemical sensors.28 These methodologies 
exploit host-guest type chemistries whereby the interaction leads to measurable changes in the 
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optoelectronic properties of the host, hence facilitating the detection of the target analyte. As a 
result, in-depth understanding of the intermolecular interactions that would foster selective 
binding between the chemical sensor (host) and the target analyte (guest) is deemed critical in 
the development of novel sensing platforms for biologically relevant analytes, such as 
psychoactive substances. In most cases, those interactions are non-covalent in nature, which 
although individually weak, play a critical role in defining the overall binding affinities and 
associate conformational changes in a plethora of key processes that are not limited to protein-
binding interactions and drug development but that further span to other topical areas of research 
such as charge-transfer mechanisms in optoelectronic materials.29–34 
Along those lines, understanding any structural causation upon interaction between ligand and 
receptor would be invaluable in aiding the development of selective chemical sensors for their 
target analytes, by guiding the selection of peripheral substitutions performed on core motifs 
with the desired optoelectronic properties. To that end, computational approaches such as those 
denoted by molecular docking studies are nowadays ubiquitous in providing insightful structural 
and enthalpic information regarding three-dimensional ‘weakly’ bonded host-guest complexes, 
such as those formed between ligands and receptors in target proteins.25,30,32,33 In molecular 
docking, each potential orientation of both the ligand and the receptor in the supramolecular 
complex is referred to as a pose. Poses are evaluated based on the ligand-protein affinity utilising 
so-called scoring functions, where a ‘good score’ is attributed to potentially successful binding 
interactions. In short, scoring functions can be broadly divided into knowledge-based scoring 
functions and energy component methods. The former are derived using the probability of 
known relevant intermolecular interactions from a large database. In turn, energy component 
methods denote scoring functions where the free energy (ΔG) following a supramolecular 
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binding interaction process can be broken down into the sum of contributions such as the specific 
ligand-protein interactions as well as conformation changes upon binding.35 However, in the 
quest to rationally develop novel sensing platforms for target analytes that exploit host-guest 
chemistries, knowledge of individual enthalpic contributions from amino acid residues would 
pave the way for the realisation of superior technologies. Despite the large number of amino acid 
residues surrounding the ligands in the binding pocket of target proteins, the strength of the 
overall interaction is often uniquely dictated by a few key residues. These key amino acids can 
be called so due to exhibiting close interatomic distances with respect to the ligand and/or 
presenting appropriate relative orientation as to maximise the strength of the interaction.35 In 
addition, on formation of the host-guest complex, both the binding pocket and ligand are likely 
to adopt an ad-hoc conformation. The extend of those structural changes is also evaluated by 
scoring functions. As a result, an aspect of interest in molecular docking studies is the 
identification of biologically relevant conformations within the landscape of all possible three-
dimensional arrangements. Whilst relevant protein conformations can be afforded by means of 
protein X-ray crystallography, NMR studies or more often, by homology modelling, the 
biological relevance of the yielded conformations of ligands denotes an on-going debate within 
the molecular docking community,25,36 and can be partially ascribed to the intrinsically large 
structural flexibility of small molecules. In most cases and in the absence of crystallographic 
data, the geometries of ligands are obtained by following geometry optimisation protocols using 
molecular mechanics, which are implemented in most commercially available molecular docking 
packages.25,26,37 The latter, whilst denoting an appropriate approach for the rapid screening over a 
large dataset of potential energy minima, lacks the accuracy of higher level quantum mechanics 
calculations.25 Although in some cases, conformations of systems in the crystal structures of 
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protein-ligand complexes are significally less stable than energy minimum geometries,38–40 
access to experimentally determined crystallographic data of biologically relevant analytes is of 
paramount importance. This is particularly relevant in cases where crystallographic information 
is scarce, such as in the case of psychoactive substances. 
 
 
Figure 2. Chemical structures for mexedrone, MDAI and phenibut. 
 
Motivated by these shortcomings, herein we report an in-depth in-silico evaluation of the binding 
of psychoactive substances to target receptors in monoamine transporters, particularly focused on 
the contributions of individual amino acid residues to such binding event. Among the plethora of 
psychoactive substances, we selected MDAI, mexedrone and phenibut in our study, based on 
their current relevance, available literature and their known interaction with the monoamine 
transporters.22,41–45 To be the best of our knowledge, this is the first study carrying out an in-
depth investigation of the individual amino acid contributions to the overall binding interaction 
of psychoactive substances to receptors of those target proteins. To achieve that, we first 
optimised the geometries of the selected psychoactive substances (ligands) by means of 
molecular as well as quantum mechanics approaches and compared them to experimentally 
solved crystal structures to further understand their structural flexibility. Subsequently, the three 
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optimised geometries for each ligand were docked against the three monoamine transporter 
proteins, namely the DAT, the NET and the SERT. Evaluation of their docking scores highlights 
the critical impact of the conformation of the ligand, particularly in those structures with greater 
flexibility such as phenibut. Importantly, we observed that whilst the computed docking scores 
for the three MATs conformed to the experimentally determined potency trends for mexedrone, 
that was not the case for MDAI. With the aim of further investigating these observations and 
aiding in the rational design of superior point-of-care detection methodologies for psychoactive 
substances exploiting the modulation of the optoelectronic properties of the sensor upon 
interaction with the target analyte, we went on to quantify the individual contributions by means 
of quantum mechanics calculations. To do that, the three-dimensional coordinates of both ligand 
and receptors were extracted from highest ranked poses and the intermolecular interactions of the 
psychoactive substance with each nearest neighbouring amino acid residue calculated using a 
dimeric model. We observed that pharmacological trends were accounted for by our calculations 
in all cases. Importantly, in-depth evaluation of the individual amino acid contributions revealed 
the dominant role played by key amino acid residues, particularly those aromatic such as 
phenylalanine and tyrosine, in determining the strength of the binding and anticipate the 
importance of judiciously selecting peripheral substitutions in chemical sensors as well as core 
motifs to favour selective recognition. As a result, we believe this study to be of interest not only 
for those using computational approaches to understand protein-ligand interactions but more 
importantly, to the increasingly large community devoted to the development of superior point-
of-care methodologies for biologically relevant analytes. 
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EXPERIMENTAL SECTION 
Reagents and materials. Hydrochloric acid was purchased from Fisher Scientific and used as 
received without any further purification. Reference standard materials (purity ≥ 98%) for 
mexedrone, MDAI and phenibut were all purchased from Chiron AS (Trondheim, Norway) 
under UK Home Office License and used as supplied.   
Preparation of crystals for single crystal X-ray Diffraction Analysis. Single crystals for 
mexedrone, MDAI and phenibut were obtained by slow evaporation of cooled acidified (HCl) 
water solutions. 
Crystal structure determination. All crystallographic measurements were made at 123(2) K 
with an Oxford Diffraction Gemini S diffractometer and monochromated Cu radiation (λ = 
1.54184 Å). Programs from the SHELX suite were used for structure solution and refinement.46 
Refinement was to convergence against F2 using all unique reflections. Non H-atoms were 
refined anisotropically. All H atoms bound to C were observed in difference maps but were 
included in the final model as riding atoms. The H atoms bound to O or to N were refined freely 
and isotropically. Selected crystallographic and refinement parameters are given in the 
supporting information (Table SI1.1). The crystal structure of mexedrone·HCl reported herein 
only exhibits small differences with respect to the one previously solved.47 CCDC 1989619 to 
1989621 contain the supplementary crystallographic data for this structure. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.ac.uk/data_request/cif.  
Molecular docking studies. Binding sites for all three monoamine transporters were elucidated 
utilising the Molecular Operating Environment (MOE)48 and then cross referenced with available 
literature to ensure that all residues considered to be important to binding were contained within 
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the putative binding sites defined.15,49 For the dopamine and norepinephrine transporters, the 
crystal structure of Drosophila dopamine transporter in complex with the psychostimulant D-
amphetamine (accession number 4XP9)15 and cocaine (accession number 4XP4)15 were used, 
respectively. The X-ray structure of the ts3 human serotonin transporter complexed with S-
citalopram at the central site and Br-citalopram at the allosteric site was used for the serotonin 
transporter (accession number 5I75).49 Binding was carried out in the central site in all cases. 
Cavities were defined by probe radius 1 and 2 of 1.4 and 1.8 Å respectively, connection distance 
of 2.5 Å and a minimum size of 3 residues. 
Geometries for protonated forms of the three ligands were optimised by means of MMFF9450 
force field as built in MOE’s ‘quick-prep’ methodology as well as M06-2X51 density functional 
at 6-31G(d) level as implemented in Spartan ‘18 (v. 1.3.0),52 without applying any constrains 
(Table S2.1-7). Geometries optimised with the latter were subjected to infrared analysis returning 
non negative frequencies in all cases, consistent with a true equilibrium minimum.37,53,54 It is 
noteworthy that the crystal structure conformation was selected as the starting point for the 
optimisation by quantum mechanics. In turn, molecular mechanics optimisation was carried out 
imputing the geometries as SMILES strings. Experimentally obtained crystal structure 
geometries were subjected to hydrogen atom optimisation prior to docking studies following our 
previously reported method,55 employing M06-2X51 density functional at the 6-31G(d) level as 
implemented in Spartan ’18 (v. 1.3.0).52 Single point energies of the H-optimised crystal 
structure geometries as well as MMFF94 optimised systems were calculated at the M06-2X/6-
31G(d) level for further comparison. 
Protein models were prepared prior to induce fit docking studies in MOE employing the 
MMFF94 force field.50 Docking was carried out within MOE package employing the triangle 
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matcher placement method with a rigid receptor refinement to allow for a better comparison of 
the results for different geometries of the ligands. Poses were selected based on London ΔG and 
Generalised-Born volume integral/weighted surface area (GWVI/WSA) energy component 
method scoring functions, with the number of docked poses generated set to a maximum of 30 or 
until the conformation of the ligand reached a default RMSD cut-off value of 3.0 Å. 
Computation of intermolecular interactions. MOE induce fit docking outputs (coordinates) 
were extracted for all investigated protein-ligand complexes and nearest neighbour amino acid 
residues selected using an interatomic distance cut-off value of 4.5 Å. Binding energies between 
each ligand and nearest neighbour amino acid residues were then calculated within the 
framework of a dimeric model by means of Truhlar’s density functional M06-2X51 at the 6-
311G(d) level as implemented in Spartan ’18 (v.1.3.0) software.52 All computed intermolecular 
interactions were corrected for Basis Set Superposition Error (BSSE) by means of the 
counterpoise method of Boys and Bernardi.56  
 
RESULTS AND DISCUSSION 
Structural flexibility of the ligands. Most small molecules are intrinsically characterised by a 
large structural flexibility, which inevitably leads to concerns when trying to obtain biologically 
relevant conformations for docking studies.25,38 It is noteworthy that in some cases, 
experimentally determined conformations by means of X-ray crystallography are significantly 
less stable than the geometry at the global minimum and in some cases do not even correspond to 
geometries at local minima.38–40 However, these are critical in the assessment of computationally 
optimised geometries. As a result, we deemed of interest to investigate in detail the yielded 
ligand conformations that the three psychoactive substances exhibit by means of commonly used 
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molecular mechanics protocols implemented in commercial molecular docking software with 
those obtained by means of quantum mechanics calculations as well as X-ray crystallographic 
studies. For all three protonated ligands, namely mexedrone, MDAI and phenibut, we report 
molecular mechanics as well as experimental crystal structure geometries which are less stable 
than their conformations yielded by quantum mechanics calculations. In short, whilst the 
differences with the crystal structures can be attributed to interactions with neighbouring 
monomers as well as solvent molecules during the crystal growth process as opposed to quantum 
mechanics calculations, the comparison with molecular mechanics yielded geometries could be 
associated to starting conformations in those calculations.  
In the case of both MDAI and mexedrone, the largest differences were observed between 
quantum and molecular mechanics optimised conformations (ΔE = 24.85 kJ mol-1) and between 
optimised quantum mechanics and experimental crystal structure geometries (ΔE = 24.53 kJ mol-
1), respectively. Interestingly, we compute a significantly less stable molecular mechanics 
conformation of phenibut when compared to its crystal structure counterpart (ΔE = 86.84 kJ mol-
1) and to a greater extend with respect to its quantum mechanics counterpart (ΔE = 110.07 kJ 
mol-1). In some cases, large conformational reorganisation energies can be attributed to 
variations in bond lengths between the two geometries.57 However, here detailed analysis of the 
variations in bond lengths for all investigated ligands reveals no significant changes that could 
account for the observed energy differences between conformations. Instead, we observed that 
unlike for the different yielded conformations for MDAI and mexedrone, the optimised geometry 
of phenibut by means of molecular mechanics exhibits a critical structural difference with 
respect to the quantum mechanics optimised geometry as well as experimental crystal structure 
geometry as illustrated in Figure 3. It should be noted that the geometry of the crystal structure 
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was utilised as the starting point in quantum mechanics geometry optimisation calculations, 
whereas molecular mechanics geometry optimisations were performed from SMILES strings 
inputs, hence lacking three-dimensional information. 
 
 
Figure 3. Phenibut conformations yielded by quantum mechanics optimisation (left), docking 
studies using molecular mechanics (centre) and crystal structure (right). 
 
Figure 3 illustrates the conformations of phenibut yielded for the three different approaches 
utilised in this work. The conformations particularly differ on the orientation of the protonated 
amine with respect to the plane of the benzene ring, with the crystal structure and quantum 
mechanics geometries exhibiting an exo-type conformation of the amine group with measured 
dihedral angles of, θ = 178.26 and 148.93°, respectively. In turn, the optimised geometry by 
molecular mechanics from SMILES strings is characterised by an endo-type conformation (θ = 
50.72°) where the amine is closely situated above the plane of the benzene ring, which we 
anticipate could lead to reduced number of intermolecular interactions with neighbouring amino 
acid residues. As a result, we investigated this further. It could be argued that the conformation 
obtained by molecular mechanics denotes a local minima situated in a different region to that of 
the energy minima yielded by quantum mechanics, along the potential energy surface. To further 
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evaluate this observation, we went on to optimise the molecular mechanics geometry by means 
of quantum mechanics. We observed that the newly optimised geometry (Table S2.5) exhibits no 
negative frequencies on the computed infrared spectrum and hence conforms to the geometry of 
an energy minima. The resulting conformation, similarly to the case of its molecular mechanics 
counterpart, is characterised by an endo-type arrangement of the amine with respect to the 
benzene ring (θ = 51.59°). As a result, these findings highlight the importance of evaluating the 
conformations of ligands, particularly in molecular docking studies. In the following, we 
examine in detail the docking scores obtained for the different conformations of the three 
investigated psychoactive substances in their target proteins. 
Molecular docking studies. The ability of the three psychoactive substances to interact with 
plasma membrane monoamine transporters was investigated using molecular docking studies. In 
all cases, the geometry of both ligand and protein were kept rigid upon binding to facilitate 
further evaluation of any structural causation to the interaction process. Yielded poses were rank 
ordered employing their docking scores, with the following analysis focusing on the top ranked 
pose for each conformation evaluated (Table SI3.1-9). 
 
Table 1. Computed docking scores for highest ranked poses for the different ligand geometries 
in all investigated monoamine transporters (MAT). 
Ligand Conformation MAT Docking score 
MDAI 
Quantum 
mechanics 
DAT -5.5362 
NET -5.7010 
SERT -5.0285 
Molecular DAT -5.5082 
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mechanics NET -5.6839 
SERT -4.9237 
Crystal structure 
DAT -5.5249 
NET -5.6946 
SERT -5.0389 
mexedrone 
Quantum 
mechanics 
DAT -5.7706 
NET -5.6254 
SERT -5.1283 
Molecular 
mechanics 
DAT -4.8010 
NET -4.8016 
SERT -5.8647 
Crystal structure 
DAT -4.3128 
NET -5.9837 
SERT -4.9222 
phenibut 
Quantum 
mechanics 
DAT -4.8739 
NET -5.5350 
SERT -4.6779 
Molecular 
mechanics 
DAT -4.3116 
NET -5.3696 
SERT -5.1323 
Crystal structure 
DAT -5.5775 
NET -5.3073 
SERT -4.9307 
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In agreement with previous studies,15,49 we report that in all investigated cases and irrespective of 
the rank order of the pose the preferred binding site was the so-called central or S1 site, which in 
the case of the serotonin transporter it is located between the helices 1, 3, 6, 8 and 10.49 Table 1 
summarises the docking scores for the highest ranked poses for the different evaluated 
conformations of each psychoactive substance in all three monoamine transporters. 
Careful analysis of these results reveal that different ligand conformations have negligible impact 
on the computed docking scores for the top poses of MDAI containing complexes, which can be 
attributed to the small flexibility of this psychoactive substance when compared to mexedrone 
and phenibut (vide supra). Our computational docking results indicate that, in agreement with 
experimental studies,19,58 MDAI acts on all three monoamine transporters. However, the often-
observed higher potency of MDAI on the NET and the SERT when compared to that on the 
DAT is not fully accounted by our docking results, hence warranting further computational 
studies on the docking of this psychoactive substance. This is particularly interesting given the 
large structural similarity between the DAT and the NET.15,49 In this regard, evaluation of the 
position of the ligand exhibiting the crystal structure geometry within the cavity of the central 
binding site of the three MATs is consistent with small differences in the scoring values for 
docking onto the DAT and  the NET, attributed to similar sequence of nearest neighbouring 
amino acids bordering the ligand. Although scoring factors consider other aspects of the binding 
process and not just the intermolecular interactions, the latter can be associated to fewer and 
longer distance interactions with amino acid residues when compared to docking on the other 
transporters and will be accordingly analysed in-depth in the following section. 
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Highest ranked poses for mexedrone and phenibut docking on the MATs do, on the contrary, 
exhibit docking scores which vary according to the conformation used. This can be ascribed to 
their large structural flexibility and the observed conformational changes upon 
optimisation/experimental crystal growth, particularly in the case of phenibut. In line with our 
previous observations on the structural variations for the different conformers of phenibut, we 
report these to bear greater impact on the yielded docking scores for the DAT (S = -4.8739, -
5.5775 and -4.1316 for quantum mechanics, crystal structure and molecular mechanics 
geometries respectively). In fact, the docking score for the molecular mechanics optimised 
geometry was the lowest computed for all investigated ligand-MAT pairs. Underpinned by the 
detailed structural analysis of the different yielded conformations of the ligands, we associate 
this finding to the observed endo-type arrangement of the protonated amine with respect to the 
benzene core, hence resulting in fewer intermolecular contacts with bordering amino acid 
residues. 
Whilst, to the best of our knowledge, there is a lack of pharmacological studies on the 
interactions of phenibut with the monoamine transporters, experimental observations made for 
mexedrone interactions indicate higher potency values for the NET.47 Along those lines, it is of 
note that our computed docking scores employing the geometry of the crystal structure (Table 1) 
are in agreement with these observations, whereas scoring values for the conformations obtained 
following the molecular docking protocol do not conform to the experimental observations. 
Furthermore, the score for the docking of the crystal structure conformation of mexedrone onto 
the NET is the highest we report for all investigated systems, largely attributed to close 
intermolecular interactions with phenylalanine (43, 319 and 325) residues (Figure S4.58-60).   
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In light of these findings and to aid in the development of superior sensing platforms for these 
psychoactive substances exploiting host-guest type chemistries, in the following we will explore 
in detail the determined intermolecular interactions between the crystal structure geometries for 
each ligand and nearest neighbour amino acid residues in all three monoamine transporters. 
Intermolecular interactions, ΔECP. Intermolecular interaction energies were computed for the 
binding of the crystal structure geometries of the psychoactive substances and nearest 
neighbouring amino acid residues in each monoamine transporter, which were obtained from 
molecular docking studies. Firstly, we deemed of interest to compare the order of the docking 
scores, which are calculated based on different contributions and not solely the strength of the 
interaction, with that of the overall computed intermolecular interaction in each evaluated case, 
ΣΔECP. It is noteworthy that for the two psychoactive substances for which pharmacological data 
is available, namely MDAI and mexedrone, our computed intermolecular interactions conform to 
the potency trends observed experimentally for the three MATs. Whilst docking studies were 
also in agreement with experimental data in relation to the activity of mexedrone, this was not 
the case for the aminoindane MDAI, for which docking results predicted the highest potency on 
the NET (Table 1). In turn, ΣΔECP results are consistent experimental studies which reveal 
greater activity on the SERT, thus highlighting the importance of the approach proposed herein. 
Predicted trends employing computed intermolecular interactions for phenibut agree with those 
obtained by molecular docking (vide supra). 
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Table 2. Computed counterpoise-corrected intermolecular interactions, ΔECP (kJ mol-1) for 
MDAI with nearest neighbouring amino acid residues within the binding sites of the DAT, NET 
and SERT monoamine transporters (Figure S4.1-34). 
DAT NET SERT 
Amino acid ΔECP Amino acid ΔECP Amino acid ΔECP 
Ala 117 -8.84 Ala 117 -76.81 Ala 96 -44.76 
Asp 46 21.53 Asn 125 -11.59 Asp 98 20.15 
Asp 121 -13.89 Asp 46 6.32 Gly 338 5.60 
Gly 425 3.57 Asp 121 -3.87 Gly 442 -3.25 
Phe 43 -44.65 Gly 425 -6.86 Ile 172 -2.87 
Phe 319 -52.99 Phe 43 -12.69 Phe 335 -54.61 
Phe 325 -9.35 Phe 325 -22.21 Phe 341 -3.23 
Ser 421 -5.16 Ser 421 -7.20 Ser 336 -39.33 
Ser 422 -6.70 Ser 422 -23.12 Ser 438 -6.55 
Tyr 124 -28.32 Ser 426  -13.92 Tyr 95 -122.46 
Val 120 -13.97 Tyr 124 -16.39 Tyr 176 -14.73 
 Val 120 -24.91  
 
Table 2 summarises the computed intermolecular interactions for MDAI with nearest neighbour 
amino acid residues in all three monoamine transporters. Interestingly, despite the different 
orientation of MDAI within the pocket of the DAT and the NET, we identified that 10 out of the 
12 nearest neighbours that facilitate binding to the NET were also present in the complex with 
the DAT, albeit exhibiting different computed intermolecular interactions as a result of the 
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distinct relative three-dimensional orientation (ΔECP (Ala 117) = -8.84 and -76.81 kJ mol-1 for 
DAT and NET respectively). In addition, none of these particular amino acid residues contribute 
to the large computed binding of MDAI to the SERT (ΣΔECP = -266.04 kJ mol-1). 
 
 
Figure 4. Spacefill illustration of the interaction between MDAI and Ala 96 (left), Phe 335 
(centre) and Tyr 95 (right) residues in the binding to the SERT.  
 
In fact, we report the largest overall intermolecular interactions for the binding of MDAI to the 
SERT, with noteworthy stabilising contributions from Ala 96 (ΔECP = -44.76 kJ mol-1), Phe 335 
(ΔECP = -54.61 kJ mol-1) and especially Tyr 95 (ΔECP = -122.46 kJ mol-1) residues, all of which 
exhibit interactions that engage their electronegative carbonyl oxygen atoms and positively 
charged amine of the ligand (Figure 4). The observed greater interaction with the Tyr 95 residue 
can be further associated to: i) the closer distance of the previously described interaction and ii) 
the additional T-shape type interaction between the phenylalanine phenol and the MDAI core. 
The latter finding exemplifies that whilst selectivity towards a particular analyte in the design of 
chemical sensors via judicious selection of peripheral subsitutions is appropriate, adequate 
selection of core motifs also plays a critical role. 
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Similarly to the observations made for the binding of MDAI, we observe a large number of 
common amino acid residues (11 out of 14 nearest neighbour NET residues) responsible for the 
interaction of mexedrone within the central cavity of the DAT and the NET. Despite the latter, 
there are significant differences in the overall computed strength of the binding of the ligand to 
those monoamine transporters. Whilst we compute mexedrone largest interaction energy to the 
NET, we report the lowest value for the DAT, with the overall interaction to the SERT 
somewhere in between (ΣΔECP = -105.20, -182.53 and -158.53 kJ mol-1 for binding to the DAT, 
the NET and the SERT respectively). The circa two-fold increase in the ΣΔECP on progression 
from the DAT to the NET can be particularly associated to the contributions of two amino acid 
residues, namely Asp 46 and Phe 43. In evaluating this finding, we observed that the large 
destabilising interaction of mexedrone with Asp 46 in the binding to the DAT, which can be 
associated to a close contact between the electropositive aspartic hydrogen atom of the acid 
group and the protonated amine of the ligand, becomes almost negligible on binding to the NET 
(ΔECP (Asp 46)= 28.76 and 2.48 kJ mol-1 for DAT and NET respectively). On the contrary, the 
establishing energy computed for the mexedrone-Phe 43 pair in th DAT (ΔECP = -24.44 kJ mol-
1), was observed to increase significantly in the case of the binding within the NET S1 site (ΔECP 
= -59.10 kJ mol-1). We attribute the latter to the synergistic contribution of the interaction 
between the electropositive amine hydrogen atom and the electronegative carbonyl oxygen at 
2.625 Å as well as the stabilising interaction of the protonated mexedrone amine with the 
phenylalanine core. 
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Table 3. Computed counterpoise-corrected intermolecular interactions, ΔECP (kJ mol-1) for 
mexedrone with nearest neighbouring amino acid residues within the binding sites of the DAT, 
NET and SERT monoamine transporters (Figure S4.35-74). 
DAT NET SERT 
Amino acid ΔECP Amino acid ΔECP Amino acid ΔECP 
Ala 44 -16.46 Ala 44 -12.72 Asp 98 6.1447 
Ala 48 3.01 Ala 117 -9.05 Glu 493 -68.37 
Asp 46 28.76 Asp 46 2.48 Ile 172 -4.22 
Asp 121 -5.72 Asp 121 -1.28 Phe 335 -22.84 
Gly 322 -1.46 Gly 322 -2.82 Ser 438 -6.08 
Gly 425 6.84 Gly 452 2.22 Thr 497 -15.74 
Leu 321 -8.35 Leu 321 -9.04 Tyr 95 -20.49 
Phe 43 -24.44 Phe 43 -59.10 Tyr 175 -16.03 
Phe 319 -50.63 Phe 319 -32.44 Tyr 176 -13.08 
Phe 325 2.22 Phe 325 -18.64 Val 501 2.18 
Ser 320 -5.33 Ser 320 -21.18  
Ser 421 -6.11 Ser 421 0.45 
Ser 422 2.71 Tyr 124 -12.77 
Tyr 124 -22.54 Val 120 -8.64 
Val 120 -7.70  
 
Lastly, we focus on the individual amino acid contributions on the binding of phenibut to the 
different monoamine transporters. In contrast to the observations made for the other two 
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psychoactive substances where the lowest interactions were computed for the binding to the 
DAT, we report the largest overall interaction for phenibut when docked to this monoamine 
transporter (ΣΔECP = -172.07, -117.37 and -153.45 kJ mol-1 for binding to the DAT, the NET and 
the SERT respectively). Upon judicious analysis of the binding of the three ligands to the 
dopamine monoamine transporter, we attribute the larger interaction energy of phenibut (ΣΔECP 
= -158.77, -105.20 and -172.07 kJ mol-1 for binding of MDAI, mexedrone and phenibut to the 
DAT, respectively) to i) a diminish of the destabilising interaction with an aspartic acid residue 
(Asp 46) and ii) the increase of the binding interaction to a tyrosine residue (Tyr 124).  
 
 
 
Figure 5. Spacefill representation of the interaction MDAI (left), mexedrone (centre) and 
phenibut (right) with the Tyr 124 residue within the S1 site of the DAT. 
 
In relation to the differences in the computed intermolecular interactions between the 
psychoactive substances and the Asp 46 residue (ΔECP = 21.53, 28.76 and 4.01 kJ mol-1 for 
binding of MDAI, mexedrone and phenibut to the Asp 46 residue, respectively), these can be 
accounted for by means of the greater interaction distance in the case of the binding to phenibut 
as a result of a different three-dimensional arrangement of the ligand within the central cavity of 
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the transporter. Likewise, the observed ca two-fold increase in the stabilising intermolecular 
interaction computed for the binding the ligands to the tyrosine (Tyr 124) on progression from 
MDAI and mexedrone to Phenibut (ΔECP = -28.32, -22.54 and -57.07 kJ mol-1 for binding of 
MDAI, mexedrone and phenibut to the Tyr 124 residue, respectively) can also be attributed to 
critical changes in the relative ligand-receptor orientation within the S1 site of the DAT. In this 
case, we observe that whilst binding of both MDAI and mexedrone is facilitated by close T-
shape interactions aromatic moieties of the ligands and the benzene core of the residue, the 
increase in the computed ΔECP is associated to protonated phenibut amine with the core of the 
amino acid.  
 
Table 4. Computed counterpoise-corrected intermolecular interactions, ΔECP (kJ mol-1) for 
phenibut with nearest neighbouring amino acid residues within the binding sites of the DAT, 
NET and SERT monoamine transporters (Figure S4.75-112) 
DAT NET SERT 
Amino acid ΔECP Amino acid ΔECP Amino acid ΔECP 
Ala 44 -0.65 Ala 44 -9.04 Ala 96 -27.69 
Ala 117 -15.48 Ala 48 3.74 Asp 98 8.65 
Asp 46 4.01 Asp 46 -5.14 Gly 338 -0.38 
Gly 332 -3.05 Phe 43 -29.19 Gly 442 -0.15 
Gly 425 4.53 Phe 319 -9.69 Ile 172 -4.62 
Leu 321 -9.59 Phe 325 -18.64 Leu 337 -1.23 
Phe 43 -33.13 Ser 320 -21.19 Phe 335 -50.92 
Phe 319 -15.16 Ser 421 -6.99 Phe 341 -7.74 
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Phe 325 -7.22 Ser 422 0.18 Ser 336 -13.41 
Ser 320 -8.17 Tyr 124 -12.77 Ser 438 -3.18 
Ser 421 -4.12 Val 120 -8.64 Tyr 95 -33.68 
Ser 422 -4.13  Tyr 176 -21.34 
Tyr 124 -57.07 Val 97 2.24 
Val 120 -22.84  
 
 
CONCLUSIONS 
In conclusion, the binding of topical psychoactive substances such as MDAI, mexedrone and 
phenibut to the monoamine transporters for dopamine, norepinephrine and serotonin was 
investigated to aid in the development of superior sensing platforms for these target analytes that 
exploit host-guest type chemistries. To do that, and in light of the known structural flexibility of 
most ligands and prior to docking studies, we evaluated the conformational changes of optimised 
geometries of the psychoactive substances by means of quantum as well as molecular mechanics 
and compare them to experimentally determined crystal structure geometries. Interestingly, in 
the case of phenibut it was observed that the molecular mechanics optimised geometry using 
SMILES strings input leads to a critically different conformer, where the endo-type position of 
the protonated amine contrasts with exo orientation observed in the X-ray and quantum 
mechanics optimised geometries. All conformers for each ligand were then docked against target 
receptors using molecular docking approaches. We observed that in the case of MDAI, docking 
results for top ranked poses were influenced by the conformation of the ligand and that 
experimentally determined trends for the three transporters were not well predicted by the 
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computational methodologies. In turn, computational trends obtained for the crystal structure 
conformation of mexedrone conformed to experimental observations, with a higher affinity for 
the interaction with the NET. Subsequently, these results were further evaluated by determining 
the intermolecular interactions between the crystal structure geometries of the ligands and their 
nearest neighbour amino acid residues in each monoamine transporter. We found that the overall 
interaction energy computed for MDAI was in agreement with experimental observations and 
that the computed trends for mexedrone were further ratified. In all cases, overall binding 
energies were rationally narrowed down to contributions with key amino acids, which would be 
critical in guiding the development of superior chemical sensors. In particular, the greater 
interaction of MDAI with the DAT when compared to that computed for its counterparts, 
mexedrone and phenibut was attributed to lower destabilisation upon interaction with the aspartic 
acid (46) residue and more importantly to the strengthening of the interaction with the tyrosine 
(124) residue within the S1 site of the transporter. As a result, we believe the approach herein 
detailed to be of interest for those engaged in the in-silico evaluation of protein-ligand 
interactions and to furthermore be invaluable in the development of novel chemical sensors for 
biologically relevant analytes via judicious selection of peripheral substitutions performed on 
core motifs with the desired optoelectronic properties.  
 
SUPPORTING INFORMATION  
Selected crystallographic and refinement parameters for the three crystal structures (SI1), 
cartesian coordinates for the optimised geometries of the monomers (SI2), full details for the 
docking studies (SI3) as well as capped stick illustrations of all ligand-amino acid dimers (SI4). 
Crystallographic information files are also available from the Cambridge Crystallographic Data 
  
27 
Centre (CCDC) upon request (http://www.ccdc.ca.ac.uk), CCDC deposition numbers 1989619 to 
1989621. 
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